<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="32029" end="32036" sStart="-1" offset="0" sid="null" wn="7" wnkey="write%2:36:01::" annotator="tofox" text="1. The consensus amino acids are &lt;b&gt;written&lt;/b&gt; in capital letters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="32118" end="32125" sStart="null" offset="0" sid="null" wn="5" wnkey="write%2:36:01::" annotator="tofox" text="2. Beneath each consensus amino acid are &lt;b&gt;written&lt;/b&gt; in capital letters all variants determined to be positively selected (in descending order of frequency)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="32029" end="32036" sStart="null" offset="0" sid="null" wn="5" wnkey="write%2:36:01::" annotator="tofox" text="1. The consensus amino acids are &lt;b&gt;written&lt;/b&gt; in capital letters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="32029" end="32036" sStart="null" offset="0" sid="null" wn="9" wnkey="write%2:36:03::" annotator="carichter" text="1. The consensus amino acids are &lt;b&gt;written&lt;/b&gt; in capital letters." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="2238" end="2242" sStart="null" offset="107" sid="r7.1.use.v.0602" wn="1" wnkey="use%2:34:01::" annotator="jeneale" text="Phylogenetic analyses describe divergence within a viral population, and these methods have been used to infer the selective advantages of viral variation [ 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="7667" end="7672" sStart="null" offset="292" sid="r7.sound.n.0666" wn="2147483647" wnkey="null" annotator="jeneale" text="Based on QUASI's selection map of HA, we now conclude that those mutations found in the trimer-buried portion of HA do not confer significant advantage on influenza A. That is, while the trimer-buried portion of antigenic site D includes the sound and fury of variability, it signifies nothing." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="3617" end="3627" sStart="null" offset="152" sid="r10.particular.j.0712" wn="2" wnkey="particular%5:00:02:specific:00" annotator="brubin" text="The cornerstone of selection mapping is the testing of each observed replacement mutation at each codon to identify those particular replacement mutations that are overabundant relative to silent mutations at that codon." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="26865" end="26875" sStart="null" offset="51" sid="r10.particular.j.0910" wn="2" wnkey="particular%5:00:02:specific:00" annotator="anfahmy" text="That is, if selection is neutral for any particular replacement mutation, we can calculate the incidence of each replacement mutation we expect to observe (by looking at a table of the genetic code)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="21567" end="21577" sStart="null" offset="46" sid="r10.particular.j.0766" wn="2" wnkey="particular%5:00:02:specific:00" annotator="anfahmy" text="Rather, QUASI tests the R:S of each particular replacement mutation at each codon." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="28355" end="28361" sStart="null" offset="60" sid="r8.number.n.0876" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="For each possible replacement mutation, a minimum number of mutations will need to be observed for a selective event to be detected." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="25202" end="25208" sStart="null" offset="35" sid="r8.number.n.0520" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="The numerator, R, is the number of point mutations that lead from the consensus codon to the target amino acid." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="28527" end="28532" sStart="null" offset="79" sid="r9.level.n.0777" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="This minimum number differs depending on the consensus codon and the level of significance." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="13353" end="13359" sStart="null" offset="119" sid="r9.level.n.0963" wn="2" wnkey="level%1:26:01::" annotator="cgozo" text="The obvious answer is that mutations provide escape not from direct B-cell immunity but from other levels of immunity, such as T-cell immunity [including major histocompatibility complex (MHC) presentation] or indirect Ab immunity via Ab-dependent cellular cytotoxicity (where gp120 molecules found on infected cell surfaces are monomers)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="28659" end="28664" sStart="null" offset="99" sid="r9.level.n.0384" wn="2" wnkey="level%1:26:01::" annotator="brubin" text="We have calculated the minimum number of mutations needed to achieve the 5% significance level." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="31072" end="31076" sStart="null" offset="10" sid="r10.high.j.0176" wn="1" wnkey="high%3:00:02::" annotator="brubin" text="Extremely high false positive rates (up to 70%) were found for extremely short branch lengths (maximum at 0.001)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="863" end="867" sStart="null" offset="67" sid="r10.high.j.0164" wn="1" wnkey="high%3:00:02::" annotator="brubin" text="Attributed in part to antigenic drift are the moderately high failure rate and the short-lived efficacy of influenza vaccines [ 6], the failure of synthetic foot-and-mouth disease virus vaccines [ 7], and the inability of recombinant HIV vaccines to provide complete protection against field strains of the virus [ 8]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="7742" end="7747" sStart="null" offset="12" sid="r10.find.v.0582" wn="4" wnkey="find%2:32:00::" annotator="anfahmy" text="While QUASI finds that antigenic sites A-C are significantly associated with positively selected variation, this association may be a simple consequence of the sites' surface exposure." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="12354" end="12358" sStart="null" offset="136" sid="r7.1.face.n.0095" wn="6" wnkey="face%1:15:00::" annotator="veweser" text="QUASI's findings may be consistent with the existence of gaps in the carbohydrate groups thought to mask the silent face from gp120 from immune surveillance." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="11906" end="11910" sStart="null" offset="136" sid="null" wn="2147483644" wnkey="null" annotator="veweser" text="The selective advantage we find rendered by diversity in some of these regions ( e.g. , the &quot;silent face&quot;) has been attributed to neutral drift [ 44, 45], thus QUASI's results run counter to previous interpretations." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="11906" end="11910" sStart="null" offset="136" sid="r7.1.face.n.0917" wn="2147483644" wnkey="null" annotator="veweser" text="The selective advantage we find rendered by diversity in some of these regions ( e.g. , the &quot;silent face&quot;) has been attributed to neutral drift [ 44, 45], thus QUASI's results run counter to previous interpretations." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="12841" end="12845" sStart="null" offset="242" sid="r7.1.face.n.0605" wn="6" wnkey="face%1:15:00::" annotator="veweser" text="A &quot;non-neutralizing&quot; face has been identified where binding Abs generally do not neutralize HIV when gp120 is oligomerized [ 45, 47]; these data were interpreted as indicating that the non-neutralizing face is occluded in the trimer and that binding Abs are raised against shed gp120 monomers." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="11906" end="11910" sStart="null" offset="136" sid="null" wn="2147483644" wnkey="null" annotator="jeneale" text="The selective advantage we find rendered by diversity in some of these regions ( e.g. , the &quot;silent face&quot;) has been attributed to neutral drift [ 44, 45], thus QUASI's results run counter to previous interpretations." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="11906" end="11910" sStart="null" offset="136" sid="null" wn="5" wnkey="face%1:18:00::" annotator="cgozo" text="The selective advantage we find rendered by diversity in some of these regions ( e.g. , the &quot;silent face&quot;) has been attributed to neutral drift [ 44, 45], thus QUASI's results run counter to previous interpretations." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="11906" end="11910" sStart="null" offset="136" sid="null" wn="2147483644" wnkey="null" annotator="brubin" text="The selective advantage we find rendered by diversity in some of these regions ( e.g. , the &quot;silent face&quot;) has been attributed to neutral drift [ 44, 45], thus QUASI's results run counter to previous interpretations." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="12630" end="12634" sStart="null" offset="31" sid="r7.1.face.n.0799" wn="6" wnkey="face%1:15:00::" annotator="brubin" text="A &quot;non-neutralizing&quot; face has been identified where binding Abs generally do not neutralize HIV when gp120 is oligomerized [ 45, 47]; these data were interpreted as indicating that the non-neutralizing face is occluded in the trimer and that binding Abs are raised against shed gp120 monomers." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="15471" end="15475" sStart="null" offset="63" sid="r7.1.face.n.0695" wn="6" wnkey="face%1:15:00::" annotator="brubin" text="Nor are QUASI's results incompatible with the silent face being silent to B-cell immunity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="15359" end="15363" sStart="null" offset="287" sid="r7.1.face.n.0651" wn="6" wnkey="face%1:15:00::" annotator="brubin" text="Thus, because positively selected gp120 variants found throughout gp120 may be selected by T-cell immunity, QUASI's finding that the non-neutralizing face includes positively selected variants is not at odds with models where the non-neutralizing face forms the gp120 trimer interface." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="18535" end="18544" sStart="null" offset="60" sid="r8.1.different.j.0765" wn="1" wnkey="different%3:00:00::" annotator="veweser" text="For example, selection mapping of HIV isolates with different cellular tropisms will allow the determination of mutations that are positively selected depending on the host cell type." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="25303" end="25309" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="tofox" text="The &lt;b&gt;chance&lt;/b&gt; of observing r replacement mutations is given by the binomial distribution, , where n is the number of codons providing data for this position." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="25890" end="25897" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="tofox" text="In other words, we sum the &lt;b&gt;chances&lt;/b&gt; of all events that are no more likely than that of the observation." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="25303" end="25309" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="comcgeetubb" text="The &lt;b&gt;chance&lt;/b&gt; of observing r replacement mutations is given by the binomial distribution, , where n is the number of codons providing data for this position." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="25890" end="25897" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="comcgeetubb" text="In other words, we sum the &lt;b&gt;chances&lt;/b&gt; of all events that are no more likely than that of the observation." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="25303" end="25309" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="chisom" text="The &lt;b&gt;chance&lt;/b&gt; of observing r replacement mutations is given by the binomial distribution, , where n is the number of codons providing data for this position." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-2-1.anc" start="25890" end="25897" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="chisom" text="In other words, we sum the &lt;b&gt;chances&lt;/b&gt; of all events that are no more likely than that of the observation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="9925" end="9931" sStart="null" offset="31" sid="r9.appear.v.0873" wn="1" wnkey="appear%2:39:00::" annotator="veweser" text="Thus, broadly neutralizing Abs appear to be those that engage few protein positions where variation is positively selected." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="31447" end="31454" sStart="null" offset="59" sid="r9.appear.v.0549" wn="1" wnkey="appear%2:39:00::" annotator="veweser" text="For instance, if the branch length were 0.01 [as appears appropriate for HA (unpublished observation)], then the maximum false positive rate would be estimated at 32%." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-2-1.anc" start="2749" end="2755" sStart="null" offset="153" sid="r9.appear.v.0682" wn="1" wnkey="appear%2:39:00::" annotator="anfahmy" text="Such analyses of gp120 and its V regions indicate that replacement mutations are generally over-represented in this protein and thus appear to confer selective advantage to HIV-1 [ 22, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35]." />
  </sentences>
</list>